{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T18:24:16Z","timestamp":1749320656902},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0101253","type":"journal-article","created":{"date-parts":[[2014,7,2]],"date-time":"2014-07-02T04:11:25Z","timestamp":1404274285000},"page":"e101253","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Ranibizumab versus Bevacizumab for Ophthalmic Diseases Related to Neovascularisation: A Meta-Analysis of Randomised Controlled Trials"],"prefix":"10.1371","volume":"9","author":[{"given":"Bin","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haixiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Houwen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,7,1]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm0195-27","article-title":"Angiogenesis in cancer, vascular, rheumatoid and other disease","volume":"1","author":"J Folkman","year":"1995","journal-title":"Nat Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/35025220","article-title":"Angiogenesis in cancer and other diseases","volume":"407","author":"P Carmeliet","year":"2000","journal-title":"Nature"},{"key":"ref3","first-page":"335","article-title":"Role of vascular endothelial growth factor in ocular angiogenesis","volume":"19","author":"N Shams","year":"2006","journal-title":"Ophthalmol Clin North Am"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1517\/13543780903201684","article-title":"VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration","volume":"18","author":"JA Dixon","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"ref5","first-page":"4593","article-title":"Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders","volume":"57","author":"LG Presta","year":"1997","journal-title":"Cancer Res"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"d6778","DOI":"10.1136\/bmj.d6778","article-title":"Off-label prescribing in macular degeneration","volume":"343","author":"M McCartney","year":"2011","journal-title":"BMJ"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.ajo.2010.11.017","article-title":"Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file","volume":"151","author":"RJ Brechner","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"N Ferrara","year":"2006","journal-title":"Retina"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","article-title":"Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study","volume":"116","author":"DM Brown","year":"2009","journal-title":"Ophthalmology"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"PJ Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"e42701","DOI":"10.1371\/journal.pone.0042701","article-title":"A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard","volume":"7","author":"C Schmucker","year":"2012","journal-title":"PLoS One"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s11096-013-9779-7","article-title":"Bevacizumab versus ranibizumab: why are we not playing the joker?","volume":"35","author":"R Banfi","year":"2013","journal-title":"Int J Clin Pharm"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"CR Group","year":"2011","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"DF Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","volume":"382","author":"U Chakravarthy","year":"2013","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1136\/bjophthalmol-2012-302391","article-title":"A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration","volume":"97","author":"I Krebs","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1016\/j.ophtha.2013.06.020","article-title":"Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial","volume":"120","author":"L Kodjikian","year":"2013","journal-title":"Ophthalmology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/eye.2010.147","article-title":"Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial","volume":"24","author":"ML Subramanian","year":"2010","journal-title":"Eye (Lond)"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ajo.2009.10.010","article-title":"Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab\u2013a randomized controlled trial","volume":"149","author":"M Gharbiya","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1097\/IAE.0b013e31826956b7","article-title":"Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization","volume":"32","author":"P Iacono","year":"2012","journal-title":"Retina"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1755-3768.2011.02265.x","article-title":"Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation","volume":"91","author":"MB Parodi","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ajo.2013.04.026","article-title":"A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema","volume":"156","author":"AB Nepomuceno","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"D Moher","year":"2009","journal-title":"PLoS Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"AR Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"JP Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"JP Higgins","year":"2002","journal-title":"Stat Med"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/bmj.316.7124.61","article-title":"Bias in location and selection of studies","volume":"316","author":"M Egger","year":"1998","journal-title":"BMJ"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"CB Begg","year":"1994","journal-title":"Biometrics"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3341\/kjo.2013.27.4.235","article-title":"The effect of bevacizumab versus ranibizumab in the treatment of corneal neovascularization: a preliminary study","volume":"27","author":"JH Kim","year":"2013","journal-title":"Korean J Ophthalmol"},{"key":"ref30","first-page":"169","article-title":"Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients","volume":"6","author":"H Zhang","year":"2013","journal-title":"Int J Ophthalmol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1517\/14712598.2012.721772","article-title":"Anti-VEGF therapy for the treatment of glaucoma: a focus on ranibizumab and bevacizumab","volume":"12","author":"SC Park","year":"2012","journal-title":"Expert Opin Biol Ther"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3341\/kjo.2012.26.3.157","article-title":"Short-term effectiveness of intravitreal bevacizumab vs. ranibizumab injections for patients with polypoidal choroidal vasculopathy","volume":"26","author":"HJ Cho","year":"2012","journal-title":"Korean J Ophthalmol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10792-012-9562-0","article-title":"Visual and morphological outcomes of bevacizumab (Avastin(R)) versus ranibizumab (Lucentis(R)) treatment for retinal angiomatous proliferation","volume":"32","author":"K Hufendiek","year":"2012","journal-title":"Int Ophthalmol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/eye.2011.324","article-title":"Intravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathy","volume":"26","author":"HJ Cho","year":"2012","journal-title":"Eye (Lond)"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1089\/jop.2010.0195","article-title":"Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema","volume":"27","author":"BT Ozturk","year":"2011","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"e5182","DOI":"10.1136\/bmj.e5182","article-title":"The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review","volume":"345","author":"JA Ford","year":"2012","journal-title":"BMJ"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"FA Scappaticci","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1001\/jama.2008.656","article-title":"Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis","volume":"300","author":"SR Nalluri","year":"2008","journal-title":"JAMA"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"e41325","DOI":"10.1371\/journal.pone.0041325","article-title":"Effect of intravitreal anti-vascular endothelial growth factor therapy on the risk of arterial thromboembolic events: a meta-analysis","volume":"7","author":"JW Cheng","year":"2012","journal-title":"PLoS One"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1001\/archophthalmol.2010.223","article-title":"Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration","volume":"128","author":"LH Curtis","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/IAE.0b013e3182278ab4","article-title":"A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections","volume":"31","author":"MI van der Reis","year":"2011","journal-title":"Retina"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"e66721","DOI":"10.1371\/journal.pone.0066721","article-title":"Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysis","volume":"8","author":"XL Chen","year":"2013","journal-title":"PLoS One"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0101253","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T20:50:37Z","timestamp":1540327837000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0101253"}},"subtitle":[],"editor":[{"given":"Torben Lykke","family":"S\u00f8rensen","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,7,1]]},"references-count":42,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2014,7,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0101253","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,1]]}}}